Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

How do you discuss ruxolitinib cream safety concerns with your patients?

Atopic Dermatitis

You. I discussed with them that the box warnings are sort of inheritance or carried forward with the oral medication, oral jug inhibitors, and not much to do with the cream itself. And we have not seen any of those safety issues with the cream itself. I had almost more than 40 patients in the rock study, and we did not have any of those issues, issues that you see with the oral jack inhibitors. So I think it's very important to differentiate the topical versus oral safety issues, and that's how I discuss it with my patients.

How do you discuss ruxolitinib cream safety concerns with your patients?

Related CME